Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Revista Brasileira de Cancerologia (Online) |
Texto Completo: | https://rbc.inca.gov.br/index.php/revista/article/view/525 |
Resumo: | Introduction: Excessive weight gain is often reported in patients with breast cancer in hormoninotherapy with tamoxifen. Objectives: To describe the prevalence of overweight in women undergoing hormoninotherapy with tamoxifen and associated factors. Method: This was a descriptive and cross sectional study conducted in women diagnosed with breast cancer undergoing hormoninotherapy with tamoxifen. We collected information on nutritional status using anthropometric parameters such as body mass index (BMI), waist circumference and body fat percentage by bioelectrical impedance. Demographic, socioeconomic, lifestyle and clinical variables (weight, height, waist circumference, skin fold thickness and blood pressure) and dietary (24 hour recall) were collected. Results: We evaluated 24 patients aged 36-73 with a mean time of tamoxifen therapy of 16.6 months (range 4-60 months). Considering the classification of BMI, 52.4% (n=10) patients were diagnosed with overweight, 45.8% (n=11) with obesity and 1.8% (n=3) with normal weight. As for body fat percentage, two (8.3%) were overweight and 22 (91.7%) were obsese. Besides, 87.5% (n=21) were classified as having some degree of obesity. Conclusion: There was a prevalence of overweight and obesity in the evaluated women in hormoninotherapy with tamoxifen. Thus, patients, especially those who already had a history of overweight, should receive nutritional advice from the start of hormoninotherapy that promotes the maintenance of healthy weight, and should be encouraged to engage in programs of lifestyle changes. |
id |
INCA-1_f8d356a2cdf81a760117380e539cd27b |
---|---|
oai_identifier_str |
oai:rbc.inca.gov.br:article/525 |
network_acronym_str |
INCA-1 |
network_name_str |
Revista Brasileira de Cancerologia (Online) |
repository_id_str |
|
spelling |
Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with TamoxifenoEl Sobrepeso en Mujeres Diagnosticadas con Cáncer de Mama en Hormonoterapia con TamoxifenoExcesso de Peso em Mulheres com Diagnóstico de Câncer de Mama em Hormonioterapia com TamoxifenoNeoplasias da MamaHormôniosTamoxifenoGanho de PesoAvaliação NutricionalBreast NeoplasmsHormonesTamoxifenWeight GainNutrition AssessmentNeoplasias de la MamaHormonasTamoxifenoAumento de PesoEvaluación NutricionalIntroduction: Excessive weight gain is often reported in patients with breast cancer in hormoninotherapy with tamoxifen. Objectives: To describe the prevalence of overweight in women undergoing hormoninotherapy with tamoxifen and associated factors. Method: This was a descriptive and cross sectional study conducted in women diagnosed with breast cancer undergoing hormoninotherapy with tamoxifen. We collected information on nutritional status using anthropometric parameters such as body mass index (BMI), waist circumference and body fat percentage by bioelectrical impedance. Demographic, socioeconomic, lifestyle and clinical variables (weight, height, waist circumference, skin fold thickness and blood pressure) and dietary (24 hour recall) were collected. Results: We evaluated 24 patients aged 36-73 with a mean time of tamoxifen therapy of 16.6 months (range 4-60 months). Considering the classification of BMI, 52.4% (n=10) patients were diagnosed with overweight, 45.8% (n=11) with obesity and 1.8% (n=3) with normal weight. As for body fat percentage, two (8.3%) were overweight and 22 (91.7%) were obsese. Besides, 87.5% (n=21) were classified as having some degree of obesity. Conclusion: There was a prevalence of overweight and obesity in the evaluated women in hormoninotherapy with tamoxifen. Thus, patients, especially those who already had a history of overweight, should receive nutritional advice from the start of hormoninotherapy that promotes the maintenance of healthy weight, and should be encouraged to engage in programs of lifestyle changes. Introducción: El incremento de peso excesivo es a menudo relatado en pacientes con cáncer de mama en hormonoterapia con tamoxifeno. Objetivos: Describir la prevalencia de sobrepeso en mujeres sometidas a hormonoterapia com tamoxifeno y los factores asociados. Método: Tratase de un estudio descriptivo y transversal realizado en mujeres diagnosticadas con cáncer de mama sometidas a hormonoterapia con tamoxifeno. Han sido recolectadas informaciones referentes al estado nutricional mediante parámetros antropométricos como el Índice de Masa Corporal (IMC), la circunferencia de cintura y el porcentaje de grasa corporal por la bioimpedancia eléctrica. Características demográficas, socioeconómicas, estilo de vida y variables clínicas (peso, estatura, circunferencia de la cintura, pliegues cutáneos y tensión arterial) y la dieta (recordatorio 24 horas) han sido recolectadas. Resultados: Han sido evaluadas 24 pacientes en la franja de edad entre los 36 y los 73 años con un tiempo promedio de utilización del tamoxifeno de 16,6 meses (rango 4-60 meses). Teniendo en cuenta la clasificación del IMC, 52,4% (n=10) de las pacientes han sido diagnosticadas con sobrepeso, 45,8% (n=11) con obesidad y el 1,8% (n=3) con eutrofia. En cuanto al porcentaje de grasa corporal, de los (8,3%) tenían sobrepeso y 22 (91,7%), obesidad. Además, el 87,5% (n=21) han sido clasificadas con algún grado de obesidad abdominal. Conclusión: Hubo una prevalencia de sobrepeso y obesidad en las mujeres en hormonoterapia con tamoxifeno evaluadas. Así, las pacientes, especialmente aquellas que ya presentan un historial de sobrepeso, deben recibir asesoramiento nutricional desde el inicio de la hormonoterapia que promueve el mantenimiento del peso saludable, y deben ser animadas a participar en programas de cambios de estilo de vida. Introdução: O ganho de peso excessivo é frequentemente relatado em pacientes com câncer de mama em hormonioterapia com tamoxifeno. Objetivos: Descrever a prevalência de excesso de peso em mulheres submetidas à hormonioterapia com tamoxifeno e fatores associados. Método: Trata-se de estudo descritivo e transversal realizado em mulheres com diagnóstico de câncer de mama submetidas à hormonioterapia com tamoxifeno. Foram coletadas informações referentes ao estado nutricional usando parâmetros antropométricos como Índice de Massa Corporal (IMC), circunferência da cintura e percentual de gordura corporal pela bioimpedanciometria. Características demográficas, socioeconômicas, estilo de vida e variáveis clínicas (peso, estatura, circunferência de cintura, dobras cutâneas e pressão arterial) e dietéticas (recordatório 24 horas) foram coletadas. Resultados: Foram avaliadas 24 pacientes na faixa etária de 36 a 73 anos, com tempo medio de uso do tamoxifeno de 16,6 meses (variando de 4 a 60 meses). Considerando-se a classificação de IMC, 52,4% (n=10) das pacientes foram diagnosticadas com sobrepeso, 45,8% (n=11) com obesidade e 1,8% (n=3) com eutrofia. Quanto ao percentual de gordura corporal, duas (8,3%) possuíam sobrepeso e 22 (91,7%), obesidade. Além disso, 87,5% (n=21) foram classificadas como tendo algum grau de obesidade abdominal. Conclusão: Houve predomínio de sobrepeso e obesidade nas mulheres em hormonioterapia com tamoxifeno avaliadas. Assim, as pacientes, principalmente aquelas que ja apresentam histórico de excesso de peso, devem receber orientações nutricionais, desde o início da hormonioterapia, que promovam a manutenção do peso saudável, e devem ser estimuladas a se engajar em programas de mudanças no estilo de vida. INCA2013-06-28info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigos, Avaliado pelos paresapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/52510.32635/2176-9745.RBC.2013v59n2.525Revista Brasileira de Cancerologia; Vol. 59 No. 2 (2013): Apr./May/June; 201-210Revista Brasileira de Cancerologia; Vol. 59 Núm. 2 (2013): abr./mayo/jun.; 201-210Revista Brasileira de Cancerologia; v. 59 n. 2 (2013): abr./maio/jun. ; 201-2102176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporhttps://rbc.inca.gov.br/index.php/revista/article/view/525/320Lagares, Érika BarbosaSantos, Kelly de FreitasMendes, Raquel Cristina Moreira, Fabiane Aparecida Anastácio, Lucilene Rezende info:eu-repo/semantics/openAccess2021-11-29T20:11:55Zoai:rbc.inca.gov.br:article/525Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T20:11:55Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false |
dc.title.none.fl_str_mv |
Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno El Sobrepeso en Mujeres Diagnosticadas con Cáncer de Mama en Hormonoterapia con Tamoxifeno Excesso de Peso em Mulheres com Diagnóstico de Câncer de Mama em Hormonioterapia com Tamoxifeno |
title |
Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno |
spellingShingle |
Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno Lagares, Érika Barbosa Neoplasias da Mama Hormônios Tamoxifeno Ganho de Peso Avaliação Nutricional Breast Neoplasms Hormones Tamoxifen Weight Gain Nutrition Assessment Neoplasias de la Mama Hormonas Tamoxifeno Aumento de Peso Evaluación Nutricional |
title_short |
Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno |
title_full |
Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno |
title_fullStr |
Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno |
title_full_unstemmed |
Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno |
title_sort |
Overweight Breast Cancer Diagnosed Women undergoing Hormoninotherapy with Tamoxifeno |
author |
Lagares, Érika Barbosa |
author_facet |
Lagares, Érika Barbosa Santos, Kelly de Freitas Mendes, Raquel Cristina Moreira, Fabiane Aparecida Anastácio, Lucilene Rezende |
author_role |
author |
author2 |
Santos, Kelly de Freitas Mendes, Raquel Cristina Moreira, Fabiane Aparecida Anastácio, Lucilene Rezende |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Lagares, Érika Barbosa Santos, Kelly de Freitas Mendes, Raquel Cristina Moreira, Fabiane Aparecida Anastácio, Lucilene Rezende |
dc.subject.por.fl_str_mv |
Neoplasias da Mama Hormônios Tamoxifeno Ganho de Peso Avaliação Nutricional Breast Neoplasms Hormones Tamoxifen Weight Gain Nutrition Assessment Neoplasias de la Mama Hormonas Tamoxifeno Aumento de Peso Evaluación Nutricional |
topic |
Neoplasias da Mama Hormônios Tamoxifeno Ganho de Peso Avaliação Nutricional Breast Neoplasms Hormones Tamoxifen Weight Gain Nutrition Assessment Neoplasias de la Mama Hormonas Tamoxifeno Aumento de Peso Evaluación Nutricional |
description |
Introduction: Excessive weight gain is often reported in patients with breast cancer in hormoninotherapy with tamoxifen. Objectives: To describe the prevalence of overweight in women undergoing hormoninotherapy with tamoxifen and associated factors. Method: This was a descriptive and cross sectional study conducted in women diagnosed with breast cancer undergoing hormoninotherapy with tamoxifen. We collected information on nutritional status using anthropometric parameters such as body mass index (BMI), waist circumference and body fat percentage by bioelectrical impedance. Demographic, socioeconomic, lifestyle and clinical variables (weight, height, waist circumference, skin fold thickness and blood pressure) and dietary (24 hour recall) were collected. Results: We evaluated 24 patients aged 36-73 with a mean time of tamoxifen therapy of 16.6 months (range 4-60 months). Considering the classification of BMI, 52.4% (n=10) patients were diagnosed with overweight, 45.8% (n=11) with obesity and 1.8% (n=3) with normal weight. As for body fat percentage, two (8.3%) were overweight and 22 (91.7%) were obsese. Besides, 87.5% (n=21) were classified as having some degree of obesity. Conclusion: There was a prevalence of overweight and obesity in the evaluated women in hormoninotherapy with tamoxifen. Thus, patients, especially those who already had a history of overweight, should receive nutritional advice from the start of hormoninotherapy that promotes the maintenance of healthy weight, and should be encouraged to engage in programs of lifestyle changes. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-06-28 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Artigos, Avaliado pelos pares |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/525 10.32635/2176-9745.RBC.2013v59n2.525 |
url |
https://rbc.inca.gov.br/index.php/revista/article/view/525 |
identifier_str_mv |
10.32635/2176-9745.RBC.2013v59n2.525 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rbc.inca.gov.br/index.php/revista/article/view/525/320 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
INCA |
publisher.none.fl_str_mv |
INCA |
dc.source.none.fl_str_mv |
Revista Brasileira de Cancerologia; Vol. 59 No. 2 (2013): Apr./May/June; 201-210 Revista Brasileira de Cancerologia; Vol. 59 Núm. 2 (2013): abr./mayo/jun.; 201-210 Revista Brasileira de Cancerologia; v. 59 n. 2 (2013): abr./maio/jun. ; 201-210 2176-9745 reponame:Revista Brasileira de Cancerologia (Online) instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) instacron:INCA |
instname_str |
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
instacron_str |
INCA |
institution |
INCA |
reponame_str |
Revista Brasileira de Cancerologia (Online) |
collection |
Revista Brasileira de Cancerologia (Online) |
repository.name.fl_str_mv |
Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA) |
repository.mail.fl_str_mv |
rbc@inca.gov.br |
_version_ |
1797042244431118336 |